Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px
Document › Details

ERS Genomics Ltd.. (5/2/18). "Press Release: ERS Genomics Licenses CRISPR/Cas9 Genome Editing Patents to Evotec". Dublin.

Organisations Organisation ERS Genomics Ltd.
  Organisation 2 Evotec AG (FSE: EVT, TecDAX)
  Today Evotec SE (FSE: EVT, MDA X/TecDAX)
  Group Evotec (Group)
Products Product CRISPR gene editing technology
  Product 2 drug discovery services
Index terms Index term Evotec–ERS Genomics: CRISPR technology, 201804– license €na to expand Evotec’s CRISPR-based service offering from ERS Genomics Ltd
  Index term 2 ERS Genomics–MacDougall Biomedical Communications: public relations, 201606 service existent by MacDougall
Persons Person Charpentier, Emmanuelle (Helmholtz 201412 Professor at HZI)
  Person 2 Rhodes, Eric (ERS Genomics 201606– CEO before Horizon Discovery since 201201 before Sigma-Aldrich + Sangamo Biosciences)

ERS Genomics today announced a patent license agreement with Hamburg-based Evotec AG, which gains non-exclusive access to the Company’s CRISPR/Cas9 patents to expand their research services offering. ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology. Financial details of the agreement were not disclosed.

“Evotec is well known worldwide as a provider of highly specialized research solutions,” said Eric Rhodes, CEO of ERS Genomics, “This license enables them to further expand their service offering in the CRISPR gene-editing space.”

Evotec uses the CRISPR/Cas9 technology to drive its target identification platform as well as aid in the validation and unmasking of targets derived from phenotypic screening. With the integration of genome-wide arrayed CRISPR libraries into Evotec´s screening platforms, Evotec is harnessing the power of gene deletion and human, cell-based disease models to identify novel targets for downstream drug discovery programmes

ERS Genomics was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit

Contact ERS Genomics:

MacDougall Biomedical Communications
Mario Brkulj or Kara Mazey
Direct: +49 89 2420 9345 or +1 781 235 3060

Record changed: 2018-06-07


Picture [LSUS] – The Business Web Portal 650x65px

More documents for ERS Genomics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top